Biotech firm Renegade.bio and Metabolomic Diagnostics are teaming up to develop a novel pre-eclampsia risk screening test, with plans to launch in the U.S. in late 2022. The test will be jointly developed specifically for the U.S. population, improving upon available assessments by creating a personalized risk profile for individuals. It measures a panel of biomarkers in blood that serves as early indicators of pre-eclampsia risk. This provides maternal health physicians with the insights to better identify at risk pregnancies and improve their outcomes.
Preeclampsia is a pregnancy complication characterized by high blood pressure and signs of damage to another organ system, most often the liver and kidneys. Preeclampsia usually begins after 20 weeks of pregnancy in women whose blood pressure had been normal. Preeclampsia, which can cause premature birth, infant and maternal mortality, and can lead to lifelong health complications, is known to disproportionately affect first-time pregnancies as well as women of color.
Craig Rouskey, CEO and co-founder of renegade.bio explains: “Our partnership with Metabolomic Diagnostics demonstrates the mission of renegade.bio to expand community-based health solutions beyond COVID-19 testing to include women’s reproductive and sexual health, particularly among traditionally underserved communities.”
Robin Tuytten, CEO of Metabolomic Diagnostics adds: “We have been in discussions with several potential partners in the U.S. market, and we strategically selected renegade.bio for its clinical laboratory expertise in developing novel diagnostics and its mission to ensure equitable access to care within local communities. This partnership is fully aligned with our mission to enable screening of every woman at risk. We see this as the beginning of a relationship which will develop further innovative diagnostics with real impact reaching wider populations. Together we aim to significantly improve population health.”